Buy Amiodarone

Amiodarone

What is Amiodarone?

Amiodarone is a prescription-only medication (POM) listed by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It belongs to the heart-and-blood-pressure therapeutic class and is classified as a Class III anti-arrhythmic agent. The active ingredient is amiodarone itself, and it is supplied as oral pill formulations in strengths of 100 mg and 200 mg. Amiodarone is used to restore and maintain normal heart rhythm in several serious cardiac arrhythmias.

How Amiodarone Works in the Body

Amiodarone exerts its anti-arrhythmic effect through multiple electrophysiological actions:

• Potassium Channel Blockade - prolongs the cardiac action-potential, lengthening the refractory period and helping to prevent re-entry circuits.
• Sodium Channel Inhibition - reduces rapid depolarisation, slowing impulse conduction.
• Calcium Channel Blockade - diminishes automaticity in pacemaker cells.
• Beta-Adrenergic Antagonism - modestly lowers sympathetic stimulation of the heart.

These combined actions slow abnormal electrical activity, allowing the heart to beat in a regular rhythm. Oral amiodarone is well absorbed, with a large volume of distribution and a very long half-life (several weeks), which accounts for its sustained effects after dosing stops.

Conditions Treated with Amiodarone

Amiodarone is approved by the MHRA (and by the FDA/EMA) for the following indications:

• Ventricular tachycardia (VT) - life-threatening fast rhythms originating in the ventricles.
• Ventricular fibrillation (VF) - chaotic ventricular activity that can cause cardiac arrest.
• Atrial fibrillation (AF) and atrial flutter - when other anti-arrhythmics are ineffective or not tolerated.
• Supraventricular tachycardia (SVT) - certain rapidly conducted atrial rhythms.

These uses apply to adult patients for whom rhythm control is essential and who can be monitored for the drug’s known toxicities.

Evidence-Based Off-Label Uses

Some clinicians employ amiodarone for conditions that are not formally approved but have supporting clinical data:

• Persistent atrial fibrillation after cardioversion - several randomized trials show amiodarone can maintain sinus rhythm when other agents fail.
• Control of ventricular arrhythmias in congenital heart disease - case series and expert consensus recommend amiodarone when arrhythmias are refractory.

Disclaimer: Off-label use requires supervision by a qualified healthcare professional and an individualized risk-benefit assessment.

Who Should Not Use Amiodarone?

Absolute Contraindications

• Known hypersensitivity to amiodarone or any of its excipients.
• Severe sinus-node dysfunction or second- or third-degree atrioventricular (AV) block without a permanent pacemaker.
• Iodine or potassium-iodide allergy (amiodarone contains iodine).

Relative Contraindications

• Pregnancy & lactation - amiodarone crosses the placenta and is excreted in breast milk; only use if benefits outweigh risks.
• Thyroid disease - both hypo- and hyper-thyroidism can be exacerbated.
• Severe hepatic impairment - reduced metabolism may increase toxicity.
• Pulmonary disease - underlying lung conditions raise the risk of pulmonary toxicity.
• Renal dysfunction - accumulation of excipients may occur; monitor closely.

Special Populations

• Elderly patients - higher incidence of adverse effects; lower starting doses often considered.
• Patients with implanted cardiac devices - amiodarone may affect device sensing; device checks recommended after initiation.

Safety Profile and Interactions

Common Side Effects

• Photosensitivity and skin discoloration - blue-gray skin tone after prolonged use.
• Gastrointestinal upset - nausea, dyspepsia, constipation.
• Taste disturbance - metallic or bitter taste.
• Fatigue and weakness - often sub-clinical.

Serious Adverse Events

• Pulmonary toxicity - interstitial pneumonitis or fibrosis; may present with dyspnoea and cough.
• Thyroid dysfunction - hypothyroidism or hyperthyroidism due to iodine load.
• Hepatotoxicity - elevated liver enzymes, rare fatal hepatitis.
• Ocular deposits - corneal micro-deposits, usually asymptomatic but can cause visual blur.
• Cardiac conduction abnormalities - bradycardia, heart block, QT-prolongation leading to torsades de pointes.

Drug Interactions

• Warfarin - amiodarone inhibits metabolism, increasing INR; monitor anticoagulation closely.
• Digoxin - plasma levels rise; reduce digoxin dose and monitor for toxicity.
• Statins (simvastatin, atorvastatin) - risk of myopathy; dose reduction or alternative statin may be needed.
• CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) - raise amiodarone concentrations; dose adjustment required.
• Other QT-prolonging agents (e.g., sotalol, quinidine) - additive risk of torsades; avoid combined use when possible.

Food and Lifestyle Interactions

• Alcohol - may enhance hepatic toxicity; limit intake.
• Sunlight - strong photosensitivity; use sunscreen (SPF 30 or higher) and protective clothing.
• Driving or operating machinery - dizziness or visual changes may occur; avoid until tolerability is established.

If you are taking other medications, supplements, or herbal products, discuss them with your prescriber before starting amiodarone.

How to Take Amiodarone

• Formulation: Oral pills (100 mg or 200 mg). Swallow whole with a full glass of water; do not crush or chew.
• Typical Initiation: A loading regimen is often prescribed (e.g., 800-1200 mg daily for 1-3 weeks) followed by a maintenance dose of 100 mg to 200 mg once daily. Exact dosing must be individualized by the prescribing clinician.
• Maintenance: Most adults remain on 100 mg or 200 mg once daily once a therapeutic steady state is achieved.
• Renal/Hepatic Adjustments: No standard dose reduction is mandated, but clinicians may lower the maintenance dose in severe hepatic impairment or in frail elderly patients.
• With or Without Food: Amiodarone can be taken with or without meals; however, consistent timing each day improves absorption stability.
• Missed Dose: Take the missed dose as soon as remembered on the same day; do not double the next dose.
• Overdose: Symptoms may include severe bradycardia, hypotension, respiratory distress, and cardiac arrhythmias. Seek emergency medical care; activated charcoal may be considered if presentation is early.
• Discontinuation: Abrupt cessation can precipitate arrhythmia recurrence. Tapering is usually unnecessary because of the drug’s long half-life, but any change should be guided by a cardiologist.

Monitoring While on Amiodarone

• Baseline Tests: Full blood count, liver function tests (ALT, AST, bilirubin), thyroid function tests (TSH, free T4), pulmonary function tests (if pre-existing lung disease), and ECG.
• Follow-up Schedule:
• Every 3 months: Liver enzymes, thyroid function, and ECG.
• Every 6 months: Chest X-ray or high-resolution CT if respiratory symptoms develop.
• Annually: Full pulmonary function testing in long-term users.
• Clinical Review: Promptly report new shortness of breath, skin changes, visual disturbances, or unexplained fatigue.
• Device Checks: For patients with pacemakers or ICDs, device interrogation is recommended after initiation and after any dose changes.

Storing Amiodarone Safely

• Keep tablets in the original container, tightly closed, and store at room temperature (20-25 °C), protected from moisture and light.
• Do not store in the bathroom or near a kitchen sink.
• Keep out of reach of children; use child-resistant packaging if available.
• Dispose of unused pills according to local pharmacy take-back programs or NHS guidelines; do not flush down the toilet.

Medication-Specific Glossary

QT Interval

The portion of the ECG representing ventricular depolarisation and repolarisation; prolongation can predispose to torsades de pointes.

Pulmonary Fibrosis

Scarring of lung tissue that hampers gas exchange; a rare but serious adverse effect of long-term amiodarone therapy.

Thyroid Storm

An extreme form of hyperthyroidism that can be triggered by amiodarone-induced thyroid hormone release; requires urgent medical treatment.

CYP3A4

A liver enzyme that metabolises many drugs; amiodarone inhibits this enzyme, leading to increased levels of co-administered medications.

P-gp (P-glycoprotein)

A transporter protein that pumps drugs out of cells; amiodarone is both a substrate and inhibitor, affecting the distribution of other P-gp substrates.

Medical Disclaimer

This article provides educational information about amiodarone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.